TrialJournal of comparative effectiveness research2025

Elranatamab versus physician's choice of treatment in patients with triple-class exposed/refractory multiple myeloma: an updated matching-adjusted indirect comparison.

Isha Mol et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.